Text size A A

News

News

Date	Title and Summary	Additional Formats
Toggle Summary Feb 19, 2016	AGTC Selected to the University of Florida's 2016 Gator100 Annual Award Recognizes Fastest Growing Companies Owned or Led by University Graduates From Across the World	View HTML AGTC Selected to the University of Florida's 2016 Gator100 14.5 KB
Toggle Summary Feb 17, 2016	AGTC Announces New Corporate Office and Laboratory Facility Open House to be Held on February 18th	View HTML AGTC Announces New Corporate Office and Laboratory Facility 17.4 KB
Toggle Summary Feb 16, 2016	AGTC CEO to Present at the RBC Capital Markets Global Healthcare Conference on February 23, 2016 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that	View HTML AGTC CEO to Present at the RBC Capital Markets Global Healthcare Conference on February 23, 2016 15.2 KB
Toggle Summary Feb 8, 2016	AGTC Announces Financial Results for the Quarter Ended December 31, 2015 Collaboration Update: Biogen Selects Adrenoleukodystrophy (ALD) as a Discovery Program	View HTML AGTC Announces Financial Results for the Quarter Ended December 31, 2015 36.4 KB
Toggle Summary Jan 28, 2016	AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 8, 2016 GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV) based gene therapies for the treatment of rare diseases, today announced that	View HTML AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 8, 2016 15.6 KB
Toggle Summary Jan 20, 2016	AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Alpha-1 Antitrypsin (AAT) Deficiency Study Results Show That Vector DNA Persists at High Levels for 12 Months After One-Time Intramuscular Injection and Directs Sustained Expression of AAT Protein	View HTML AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Alpha-1 Antitrypsin (AAT) Deficiency 17.9 KB
Toggle Summary Jan 7, 2016	AGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases Study Results Further Validate Company's Technology Platform and Will be Used to Determine Optimal Components of ACHM-B3 Gene Therapy Clinical Development Program	View HTML AGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases 19.2 KB
Toggle Summary Jan 6, 2016	AGTC and BCM Families Foundation Announce Collaboration to Develop AAV-Based Gene Therapy for Blue Cone Monochromacy GAINESVILLE, Fla. and JUPITER, Fla. and CAMBRIDGE, Mass. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases,	View HTML AGTC and BCM Families Foundation Announce Collaboration to Develop AAV-Based Gene Therapy for Blue Cone Monochromacy 23.7 KB
Toggle Summary Jan 5, 2016	AGTC Leadership to Present at Upcoming Scientific Conferences GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced	View HTML AGTC Leadership to Present at Upcoming Scientific Conferences 19.3 KB

Print this page Email Alerts Download Library Share E-mail page

Visionary science for life changing cures.

Contact us Join our team